Adrenergic alpha-Antagonists
"Adrenergic alpha-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
| Descriptor ID |
D000317
|
| MeSH Number(s) |
D27.505.519.625.050.200.100 D27.505.696.577.050.200.100
|
| Concept/Terms |
Adrenergic alpha-Antagonists- Adrenergic alpha-Antagonists
- Adrenergic alpha Antagonists
- alpha-Antagonists, Adrenergic
- Adrenergic alpha-Receptor Blockaders
- Adrenergic alpha Receptor Blockaders
- Blockaders, Adrenergic alpha-Receptor
- alpha-Receptor Blockaders, Adrenergic
- alpha-Adrenergic Blocking Agents
- Agents, alpha-Adrenergic Blocking
- Blocking Agents, alpha-Adrenergic
- alpha Adrenergic Blocking Agents
- alpha-Adrenergic Blockers
- Blockers, alpha-Adrenergic
- alpha Adrenergic Blockers
- alpha-Blockers, Adrenergic
- alpha Blockers, Adrenergic
- alpha-Adrenergic Receptor Blockaders
- Blockaders, alpha-Adrenergic Receptor
- Receptor Blockaders, alpha-Adrenergic
- alpha Adrenergic Receptor Blockaders
- Adrenergic alpha-Blockers
- Adrenergic alpha Blockers
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic alpha-Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic alpha-Antagonists".
This graph shows the total number of publications written about "Adrenergic alpha-Antagonists" by people in this website by year, and whether "Adrenergic alpha-Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic alpha-Antagonists" by people in Profiles.
-
The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality. Urology. 2018 Sep; 119:70-78.
-
5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia. Mayo Clin Proc. 2016 Dec; 91(12):1717-1726.
-
Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clin Trials. 2009 Dec; 6(6):628-36.
-
Alpha-blocker use is associated with decreased risk of sexual dysfunction. Urology. 2009 Jul; 74(1):82-7.
-
Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA. 2008 Oct 08; 300(14):1660-4.
-
A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol. 2005 Jun; 173(6):2048-53.
-
Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization. Am J Hypertens. 2005 Apr; 18(4 Pt 1):464-9.
-
Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005 Apr; 173(4):1256-61.
-
Introduction. Urology. 2001 Dec; 58(6 Suppl 1):1-4.